Gene · 5205
Papers1,828
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 1,828
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| 14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer. | Proc Natl Acad Sci U S A | 2022 | 36252018 | PubTator, text mining | PubMed |
| Cell-impermeable staurosporine analog targets extracellular kinases to inhibit HSV and SARS-CoV-2. | Commun Biol | 2022 | 36245045 | PubTator, text mining | PubMed |
| Integrated Analyses of m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Pan-Cancer. | Int J Mol Sci | 2022 | 36232485 | PubTator, text mining | PubMed |
| NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer. | BMC Cancer | 2022 | 36224576 | PubTator, text mining | PubMed |
| PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer. | Cancer Res | 2022 | 36222718 | PubTator, text mining | PubMed |
| Galectin-3 binding protein stimulated IL-6 expression is impeded by antibody intervention in SARS-CoV-2 susceptible cell lines. | Sci Rep | 2022 | 36220879 | PubTator, text mining | PubMed |
| Lung mitochondrial DNA copy number, inflammatory biomarkers, gene transcription and gene methylation in vapers and smokers. | EBioMedicine | 2022 | 36215783 | PubTator, text mining | PubMed |
| A MYC-ZNF148-ID1/3 regulatory axis modulating cancer stem cell traits in aggressive breast cancer. | Oncogenesis | 2022 | 36207293 | PubTator, text mining | PubMed |
| The phospholipid flippase ATP8B1 is required for lysosomal fusion in macrophages. | Cell Biochem Funct | 2022 | 36169099 | PubTator, text mining | PubMed |
| A novel pyroptosis-related indicator of immune infiltration features and prognosis in breast cancer. | Front Oncol | 2022 | 36158689 | PubTator, text mining | PubMed |
| Deep whole genome sequencing identifies recurrent genomic alterations in commonly used breast cancer cell lines and patient-derived xenograft models. | Breast Cancer Res | 2022 | 36153537 | PubTator, text mining | PubMed |
| Fat Malabsorption and Ursodeoxycholic Acid Treatment in Children With Reduced Organic Solute Transporter-α (SLC51A) Expression. | JPGN Rep | 2022 | 36148443 | PubTator, text mining | PubMed |
| Targeted Proteomics for Monitoring One-Carbon Metabolism in Liver Diseases. | Metabolites | 2022 | 36144184 | PubTator, text mining | PubMed |
| Mir-29b in Breast Cancer: A Promising Target for Therapeutic Approaches. | Diagnostics (Basel) | 2022 | 36140539 | PubTator, text mining | PubMed |
| Bioinformatics Identification of TUBB as Potential Prognostic Biomarker for Worse Prognosis in ERα-Positive and Better Prognosis in ERα-Negative Breast Cancer. | Diagnostics (Basel) | 2022 | 36140469 | PubTator, text mining | PubMed |
| RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer. | Cancer Epidemiol Biomarkers Prev | 2022 | 36129803 | PubTator, text mining | PubMed |
| The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs. | Front Immunol | 2022 | 36119101 | PubTator, text mining | PubMed |
| R-spondin-3 is an oncogenic driver of poorly differentiated invasive breast cancer. | J Pathol | 2022 | 36106661 | PubTator, text mining | PubMed |
| Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer. | Front Immunol | 2022 | 36105819 | PubTator, text mining | PubMed |
| Application of metabolomics in intrahepatic cholestasis of pregnancy: a systematic review. | Eur J Med Res | 2022 | 36104763 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5205/papers?page=18